• Provectus Biopharmaceuticals reported preclinical results on May 18, 2026, from a bladder cancer study testing PV-10 given orally or delivered into the bladder, alone or combined with an anti-PD-1 therapy.
• Oral PV-10 produced the strongest overall anti-tumor activity and tolerability signal in the study, with some animals reaching the end of the study without visible bladder tumors, a result not seen in the untreated, vehicle-control, or anti-PD-1-only groups.
• PV-10 delivered into the bladder was not tolerated at the concentrations used, which the company framed as a dosing limitation rather than a lack of drug activity.
• The update is not a clinical trial readout; Provectus identified FDA acceptance of an expanded IND to enable first-in-human oral PV-10 testing as the next regulatory milestone.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Provectus Biopharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605180800PRIMZONEFULLFEED9721722) on May 18, 2026, and is solely responsible for the information contained therein.